ES2548386T3 - Formas cristalinas de saxagliptina - Google Patents
Formas cristalinas de saxagliptina Download PDFInfo
- Publication number
- ES2548386T3 ES2548386T3 ES10713211.0T ES10713211T ES2548386T3 ES 2548386 T3 ES2548386 T3 ES 2548386T3 ES 10713211 T ES10713211 T ES 10713211T ES 2548386 T3 ES2548386 T3 ES 2548386T3
- Authority
- ES
- Spain
- Prior art keywords
- saxagliptin
- crystalline forms
- crystalline
- water content
- relative humidity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 title abstract description 3
- 229960004937 saxagliptin Drugs 0.000 title abstract description 3
- 108010033693 saxagliptin Proteins 0.000 title abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000005102 attenuated total reflection Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004455 differential thermal analysis Methods 0.000 description 1
- 150000004683 dihydrates Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16791809P | 2009-04-09 | 2009-04-09 | |
| EP09157723 | 2009-04-09 | ||
| US167918P | 2009-04-09 | ||
| EP09157723 | 2009-04-09 | ||
| EP09175259 | 2009-11-06 | ||
| EP09175259 | 2009-11-06 | ||
| PCT/EP2010/054692 WO2010115974A1 (en) | 2009-04-09 | 2010-04-09 | Crystal forms of saxagliptin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2548386T3 true ES2548386T3 (es) | 2015-10-16 |
Family
ID=42935672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10713211.0T Active ES2548386T3 (es) | 2009-04-09 | 2010-04-09 | Formas cristalinas de saxagliptina |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20120088808A1 (enExample) |
| EP (1) | EP2417107B1 (enExample) |
| JP (2) | JP6088245B2 (enExample) |
| KR (1) | KR20120006047A (enExample) |
| CN (2) | CN102459170B (enExample) |
| AU (1) | AU2010233718B2 (enExample) |
| BR (1) | BRPI1006547A2 (enExample) |
| CA (1) | CA2757934C (enExample) |
| ES (1) | ES2548386T3 (enExample) |
| PL (1) | PL2417107T3 (enExample) |
| RU (1) | RU2539590C2 (enExample) |
| WO (1) | WO2010115974A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0487425A (ja) * | 1990-07-31 | 1992-03-19 | Fujitsu Ltd | 回線切り替え装置 |
| US20120088808A1 (en) * | 2009-04-09 | 2012-04-12 | Sandoz Ag | Crystal forms of saxagliptin |
| ES2546866T3 (es) * | 2009-12-16 | 2015-09-29 | Hetero Research Foundation | Polimorfos de darunavir |
| US8853430B2 (en) | 2010-05-20 | 2014-10-07 | Hetero Research Foundation | Crystalline hydrochloride salt of darunavir |
| US8410288B2 (en) | 2010-10-04 | 2013-04-02 | Teva Pharmaceutical Industries Ltd. | Polymorphs of Saxagliptin hydrochloride and processes for preparing them |
| EP2753328A1 (en) | 2011-09-07 | 2014-07-16 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dpp-iv inhibitor formulations |
| ES2487271T3 (es) | 2011-10-06 | 2014-08-20 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Formulaciones de dosificación sólidas inhibidoras de DPP-IV |
| WO2013136343A1 (en) | 2012-03-12 | 2013-09-19 | Mylan Laboratories Ltd. | Amorphous saxagliptin hydrochloride |
| US20150087686A1 (en) * | 2012-04-25 | 2015-03-26 | Enantia, S.L. | Crystalline forms of saxagliptin |
| CA2885957C (en) | 2012-05-24 | 2019-10-22 | Apotex Pharmachem India Pvt. Ltd | Salts of saxagliptin with organic acids |
| WO2014006569A2 (en) | 2012-07-02 | 2014-01-09 | Ranbaxy Laboratories Limited | Saxagliptin salts |
| WO2015067223A1 (en) | 2013-11-06 | 2015-05-14 | Zentiva, K., S. | L-tartrate salt of (1s,3s,5s)-2-[(2s)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl) acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile and process for preparation thereof |
| JP2022182181A (ja) * | 2021-05-27 | 2022-12-08 | キョーリンリメディオ株式会社 | ビルダグリプチン含有医薬品 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6032616B2 (ja) * | 1976-08-24 | 1985-07-29 | アレクサンダ− ガラツト | 高い貯蔵安定性の無水アセチルサリチル酸ナトリウム |
| US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| US7420079B2 (en) * | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
| US6995183B2 (en) * | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
| TWI354569B (en) | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
| WO2006008641A1 (en) * | 2004-07-16 | 2006-01-26 | Warner-Lambert Company Llc | Hair growth promoting agents |
| US20060035954A1 (en) * | 2004-08-11 | 2006-02-16 | Sharma Padam N | Ammonolysis process for the preparation of intermediates for DPP IV inhibitors |
| PE20090696A1 (es) * | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
| US20120088808A1 (en) * | 2009-04-09 | 2012-04-12 | Sandoz Ag | Crystal forms of saxagliptin |
-
2010
- 2010-04-09 US US13/262,652 patent/US20120088808A1/en not_active Abandoned
- 2010-04-09 JP JP2012504028A patent/JP6088245B2/ja not_active Expired - Fee Related
- 2010-04-09 EP EP10713211.0A patent/EP2417107B1/en not_active Not-in-force
- 2010-04-09 PL PL10713211T patent/PL2417107T3/pl unknown
- 2010-04-09 CN CN201080025360.7A patent/CN102459170B/zh not_active Expired - Fee Related
- 2010-04-09 RU RU2011145054/04A patent/RU2539590C2/ru not_active IP Right Cessation
- 2010-04-09 BR BRPI1006547A patent/BRPI1006547A2/pt not_active Application Discontinuation
- 2010-04-09 AU AU2010233718A patent/AU2010233718B2/en not_active Ceased
- 2010-04-09 KR KR1020117026595A patent/KR20120006047A/ko not_active Abandoned
- 2010-04-09 ES ES10713211.0T patent/ES2548386T3/es active Active
- 2010-04-09 CA CA2757934A patent/CA2757934C/en not_active Expired - Fee Related
- 2010-04-09 WO PCT/EP2010/054692 patent/WO2010115974A1/en not_active Ceased
- 2010-04-09 CN CN201410283458.2A patent/CN104016902B/zh not_active Expired - Fee Related
-
2013
- 2013-10-02 US US14/044,204 patent/US9260389B2/en active Active
-
2015
- 2015-07-16 JP JP2015141890A patent/JP2016006063A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012523395A (ja) | 2012-10-04 |
| CN104016902A (zh) | 2014-09-03 |
| US9260389B2 (en) | 2016-02-16 |
| EP2417107A1 (en) | 2012-02-15 |
| CN104016902B (zh) | 2017-10-20 |
| US20140200252A1 (en) | 2014-07-17 |
| CA2757934C (en) | 2017-12-19 |
| CA2757934A1 (en) | 2010-10-14 |
| AU2010233718B2 (en) | 2015-11-05 |
| BRPI1006547A2 (pt) | 2016-10-18 |
| WO2010115974A1 (en) | 2010-10-14 |
| JP6088245B2 (ja) | 2017-03-01 |
| CN102459170B (zh) | 2014-07-23 |
| KR20120006047A (ko) | 2012-01-17 |
| CN102459170A (zh) | 2012-05-16 |
| RU2011145054A (ru) | 2013-05-20 |
| PL2417107T3 (pl) | 2016-02-29 |
| US20120088808A1 (en) | 2012-04-12 |
| EP2417107B1 (en) | 2015-08-26 |
| AU2010233718A1 (en) | 2011-10-27 |
| JP2016006063A (ja) | 2016-01-14 |
| RU2539590C2 (ru) | 2015-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2548386T3 (es) | Formas cristalinas de saxagliptina | |
| PH12015501108B1 (en) | Treatment of pulmonary disease | |
| WO2012143497A3 (de) | Neue binder-wirkstoff konjugate (adcs) und ihre verwendung | |
| CL2008000690A1 (es) | Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras. | |
| CL2012001480A1 (es) | Sal cristalina anhidra del acido monofosforico de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea, forma a y b; metodo de preparacion; composicion farmaceutica; y su uso en el tratamiento de carcinomas, psoriasis, entre otras. | |
| PE20142350A1 (es) | Composicion para el tratamiento de aguas y metodos de uso | |
| PE20121520A1 (es) | Formulacion farmaceutica que comprende ranolazina y dronedarona en el tratamiento de fibrilacion auricular | |
| FI20096050A0 (fi) | Menetelmä kalsiumkarbonaatin ja ksylaanin saostamiseksi, menetelmällä valmistettu tuote ja sen käyttö | |
| PE20140616A1 (es) | Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecan (folfiri) | |
| MX2020005736A (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. | |
| CL2016001109A1 (es) | Composiciones y métodos útiles en el tratamiento de sintomas del tracto urinario inferior, hiperplasia prostatica benigna disfuncion eréctil | |
| CL2010000471A1 (es) | Metodo para preparar pasteles de cereales aireados que comprende introducir un cereal integral en un horno giratorio, cocer el cereal con vapor y agua, secar el cereal hasta humedad entre 10 y 17% y airear el cereal integral; un pastel de cereal integral. | |
| MX2012007032A (es) | Composiciones organicas para tratar las enfermedades relacionadas con hsf1. | |
| LT3601296T (lt) | 2-okso-tiazolo derivatai kaip a2a inhibitoriai ir junginiai, skirti naudoti gydant vėžį | |
| CL2014000623A1 (es) | Forma de dosificacion oral que comprende una dispersion del compuesto (2-(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil)-3-oxo-2,3-dihidro-1h-isoindol-4-il)-amida del acido ciclopropanocarboxilico y su uso en el tratamiento y prevencion del cancer, dolor, degeneracion macular, entre otras enfermedades. | |
| CL2012003322A1 (es) | Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer. | |
| CL2008002545A1 (es) | Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor. | |
| EA201691236A1 (ru) | Фармацевтическая композиция с содержанием селенита или содержащие селенит соединения для лечения дисплазий или карцином шейки матки | |
| IN2013MU01286A (enExample) | ||
| CL2011002967A1 (es) | Compuestos derivados de 3-oxadiazolil-5-fenil-piperidina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamient y/o profilaxis de trastornos cardiovasculares, tromboembolicos y tumorales. | |
| WO2015031198A3 (en) | Bendamustine pharmaceutical compositions | |
| JP2013147480A5 (enExample) | ||
| CN204154638U (zh) | 试验用小型拉布装置 | |
| RU2010121698A (ru) | Способ сушки древесины | |
| Miceli et al. | Correction to “First Principles Study of the LiNH2/Li2NH Transformation” |